Upadacitinib for the Treatment of Alopecia Areata – A Case Report

November 2023 in “ Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì ”

Jui-Wen Yeh, Chao‐Chun Yang

upadacitinib alopecia areata JAK1 inhibitor corticosteroids Severity of Alopecia Tool SALT score

TLDR Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

This case report details the treatment of a 21-year-old female with severe alopecia areata (AA) using upadacitinib, a selective JAK1 inhibitor. Initially, the patient had a Severity of Alopecia Tool (SALT) score of 49%, which worsened to 94% despite corticosteroid treatments. After 2 months of upadacitinib at 15 mg/day, significant hair regrowth was observed, reducing the SALT score to 34%. However, discontinuation of the medication led to rapid relapse, with the SALT score returning to 93% within 2 months. The report highlights the potential of upadacitinib as an effective treatment for AA but also notes the risk of rapid relapse upon discontinuation. Further studies are needed to establish optimal treatment protocols.

View this study on journals.lww.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series

3 citations, March 2023 in “JAAD case reports”

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study

6 citations, February 2023 in “Journal of the American Academy of Dermatology”

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

9 citations, January 2023 in “Dermatology and therapy”

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata

40 citations, August 2022 in “Frontiers in immunology”

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Related Research

10 / 10 results

research Resistant Alopecia Areata Treated with Tofacitinib

1 citations, September 2022 in “International Journal of Trichology”

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

research Alopecia Areata Flare Patterns in Children and Young Adults on Systemic Tofacitinib

7 citations, March 2021 in “Journal of the American Academy of Dermatology”

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses

11 citations, February 2021 in “Journal of Cosmetic Dermatology”

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib

13 citations, January 2020 in “Acta Dermato Venereologica”

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

research Ruxolitinib for the Treatment of Severe Alopecia Areata

37 citations, September 2018 in “Journal of the American Academy of Dermatology”

Ruxolitinib can help regrow hair in severe alopecia areata.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations, July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations, February 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

24 citations, January 2018 in “International Journal of Trichology”

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis

16 citations, January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)”

A patient with complete hair loss regrew all her hair using tofacitinib.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations, September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.